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Elevated expression and activity of matrix metalloproteinase-9 (MMP9) and decreased
contractility of cardiomyocytes are documented in diabetic hearts. However, it is unclear
whether MMP is involved in the regulation of contractility of cardiomyocytes in diabetic
hearts. In the present study, we tested the hypothesis that MMP9 regulates contractility of
cardiomyocytes in diabetic hearts, and ablation of MMP9 prevents impaired contractility
of cardiomyocytes in diabetic hearts. To determine the specific role of MMP9 in
cardiomyocyte contractility, we used 12–14 week male WT (normoglycemic sibling
of Akita), Akita, and Ins2+/−/MMP9−/− (DKO) mice. DKO mice were generated by
cross-breeding male Ins2+/− Akita (T1D) with female MMP9 knockout (MMP9−/−) mice.
We isolated cardiomyocytes from the heart of the above three groups of mice and
measured their contractility and calcium transients. Moreover, we determined mRNA and
protein levels of sarco-endoplasmic reticulum calcium ATPase-2a (SERCA-2a), which is
involved in calcium handling during contractility of cardiomyocytes in WT, Akita, and DKO
hearts using QPCR, Western blotting and immunoprecipitation, respectively. Our results
revealed that in Akita hearts where increased expression and activity of MMP9 is reported,
the rates of shortening and re-lengthening (±dL/dt) of cardiomyocytes were decreased,
time to 90% peak height and baseline during contractility was increased, rate of calcium
decay was increased, and calcium transient was decreased as compared to WT
cardiomyocytes. However, these changes in Akita were blunted in DKO cardiomyocytes.
The molecular analyses of SERCA-2a in the hearts showed that it was downregulated
in Akita as compared to WT but was comparatively upregulated in DKO. These results
suggest that abrogation of MMP9 gene prevents contractility of cardiomyocytes, possibly
by increasing SERCA-2a and calcium transients. We conclude that MMP9 plays a crucial
role in the regulation of contractility of cardiomyocytes in diabetic hearts.
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INTRODUCTION
Impaired contractility is a hallmark of all forms of heart failure
including diabetic heart failure (Mishra et al., 2010a; Luo
and Anderson, 2013). Diabetic cardiomyopathy is independent
of ischemia, valvular disease, or hypertension (Rubler et al.,
1972). In diabetics, the heart initially undergoes diastolic
dysfunction, which at advanced stage progresses to systolic
dysfunction (Boudina and Abel, 2007). Decreased contractility of
cardiomyocytes has an important role in cardiac dysfunction, and
calcium plays a crucial role in cardiomyocyte contractility. The
sarcoplasmic endoplasmic reticulum calcium ATPase (SERCA-
2a) is a calcium handling protein (Giordano et al., 1997;
He et al., 1997; del Monte et al., 1999; ter Keurs, 2012;
Luo and Anderson, 2013). In diabetic hearts SERCA-2a is
downregulated and contractility of cardiomyocytes is impaired
(Mishra et al., 2010a,b). On the other hand, expression
and activity of matrix metalloproteinase-9 (MMP9), a Zn2+-
dependent collagenase, is increased in diabetic hearts (Mishra
et al., 2010b). MMP9 is demonstrated to reduce contractility of
non-diabetic cardiomyocytes (Mishra et al., 2010c). However,
the role of MMP9 in cardiomyocytes contractility in diabetics
is unclear. To determine the role of MMP9 in cardiomyocyte
contractility, we used Insulin2 mutant (Ins2+/−) Akita mice.
Akita is a genetic, spontaneous, and chronic model of type1
diabetes (T1D), which is relevant to humans (Insulin 2 gene
of mouse is orthologous to human Insulin gene), and where
mutation of Insulin gene causes T1D (Chavali et al., 2014a).
In Akita mice, MMP9 is activated in the hearts (Mishra
et al., 2010b) and contractility of cardiomyocytes is decreased
(Mishra et al., 2010a). To assess the specific role of MMP9 on
contractility of cardiomyocytes in diabetic Akita, we generated
Ins2+/−/MMP9−/− (DKO) mice, which are diabetic but without
MMP9 gene. We have validated by genotyping, Western blotting,
zymography, and confocal microscopy that 12–14 week male
DKOmice haveMMP9 gene deleted andMMP9 activity nullified
in the heart (Mishra et al., 2012). In the present study, we
used DKO mice to determine the specific role of MMP9 on
cardiomyocytes contractility in diabetics.
METHODS
Animal Models
Male C57BL/6J,MMP9−/− and diabetic Ins2+/− Akitamice were
procured from the Jackson Laboratories (Bar Harbor, ME, USA).
They were maintained in the animal facility of the University
of Louisville (Louisville, KY) under a 12:12 h light-dark cycle.
Standard diet and water ad libitum was provided to the mice.
DKOmice were generated by cross-breeding male Ins2+/− Akita
with female MMP9−/− mice as described elsewhere (Mishra
et al., 2012; Chavali et al., 2014b). Twelve-fourteen week male
mice were used in all experiments. Animal cross-breeding,
extraction of the heart, and isolation of cardiomyocytes were
performed at the University of Louisville following protocols
approved by the Institutional Animal Care and Use Committee
of the University of Louisville.
Experimental Methods
Isolation of Ventricular Cardiomyocytes
Cardiomyocytes were isolated from the left ventricle by the
enzymatic dissociation as described elsewhere (Mishra et al.,
2010c). In brief, the heart was excised and perfused with
calcium free perfusion buffer until they get soft and limp.
Subsequently, it was perfused with digestion buffer. The left
ventricle was removed, minced under sterile conditions, and
suspended in perfusion buffer to dissociate cardiomyocytes.
These cardiomyocytes were kept in contractility buffer (135mM
NaCl, 4mM KCl, 1mM MgCl2, 10mM HEPES, 0.33mM
NaH2PO4, 10mM glucose, 10mM BDM, 1.2mM CaCl2).
Cardiomyocytes were gently pipetted up and down with a plastic
pipette (2mm tip) several times. Then the cells were transferred
to a 15ml sterile polypropylene conical tube where 10, 20, 30,
40, and 100µl of a 30mM CaCl2 solution was added at 5min
intervals. The final content of calcium was 1.2mM. Isolated
myocytes were maintained at room temperature in this buffer.
Determination of Cell Shortening and Re-Lengthening
Cardiomyocyte contractility was controlled by electrical
stimulation. Mechanical properties of isolated ventricular
myocytes were assessed by video-based edge detection. An
inverted microscope, a low light-level video camera and
a computer-based motion analyzer were used to track the
movement of cell edges. The isolated myocytes were diluted
approximately 10-fold with the contractility buffer and placed on
a Teflon glass coverslip dish mounted on the stage of an inverted
microscope (Olympus, IX-70). The cells were field stimulated
to contract by the MyoPacer field stimulator through a pair of
platinum electrodes at a frequency of 1.0Hz, pulse duration of
4ms and amplitude of 10 volts. The image of the myocyte was
obtained with an IonOptix MyoCam camera side-mounted onto
the microscope and displayed on a computer monitor using
the Soft-Edge software. Typically five individual myocytes were
recorded before replacing the myocytes with a fresh dilution
of unstimulated myocytes. This prevented exhaustion of the
myocytes due to prolonged stimulation. Twenty-twenty five
myocytes were analyzed for each heart. The cells being studied
were scanned every 8.3ms so that the amplitude and velocity of
shortening and lengthening can be recorded with good fidelity.
The displacements of cell edges at both ends of the myocyte
were detected and converted to an analog voltage signal, which
was then digitized and stored for off-line analyses. Steady-state
twitches (Malhotra and Sanghi, 1997; Mann and Spinale, 1998;
Thomas et al., 1998; Tayebjee et al., 2004; Chu et al., 2013;
Zarain-Herzberg et al., 2014) were analyzed for cell length
changes using the Soft-Edge software and averaged for each
myocyte. Cell shortening and relengthening were assessed by
time to 90% peak shortening, time to 90% relengthening, and
maximal velocities of shortening and relengthening (±dL/dt).
Intracellular Calcium Measurement
Intracellular Ca2+ influx was detected by using Fura 2-AM
(Mishra et al., 2010c). Briefly, fluorescence was measured by
loading the myocytes with 1.0µmol/L of Fura 2-AM. Cells were
illuminated at 360 nm for 0.5 s and then at 380 nm for the
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rest of the duration of recording. Fluorescence was detected
between 480 and 520 nm using a photomultiplier tube during
contraction/relaxation cycle. Intracellular Ca2+ clearance rate
was determined from the fluorescence signal decay over the time.
Ca2+ transients were analyzed in fifteen-twenty cardiomyocytes
per animal and four- seven animals per group.
RNA Extraction and Quantitative PCR (QPCR)
RNA was extracted from the isolated hearts of WT, Akita,
and DKO using Trizol kit (Thermo scientific, Waltham, MA,
USA, cat # 15596-018) following the kit’s protocol. The quality
of the extracted RNA was determined by NanoDrop-2000
spectrophotometer. Pure quality RNA with 260/280∼2.00 and
260/230∼2.00 was used for further RT-PCR and quantitative-
PCR analyses. The SERCA-2a primers were designed using
Primer3 Input. The sequences for forward and reverse primers
of SERCA-2a were 5′ TCTTCATAACACACGCCAATT 3′,
and 5′ CCCTTTGCTGCCAATTAACTA 3′, respectively.
The 18S control primer forward and reverse sequences
were 5′ GTAGTTCCGACCATAAACGA 3′ and 5′
TCAATCTGTCAATCCTGTCC 3′, respectively. Syber-green dye
(BioRad Laboratories, Hercules, CA, USA, catalog # 172-5120)
was used for Real-Time quantitative PCR (QPCR). QPCR
was performed on Bio-Rad CFX-connect system with gene
amplification program: 95◦C-3min, [95◦C-5 s, 55◦C-15 s] × 39
as per the product protocol.
Protein Extraction and Western Blotting
Tissues were lysed in RIPA buffer (Boston BioProducts, Ashland,
MA, USA, cat # BP-115). BCA protein assay was used for
protein quantification analyses with Pierce BCA protein assay
kit (Thermo scientific, Waltham, MA, USA, cat # 23227).
Absorbance was measured using Promega glow max multi
+ detection system (Promega, Madison, WI, USA). Equal
amounts of protein (30µg) were subjected to 10% SDS-PAGE
and transferred to nitrocellulose membrane. Primary antibody
used were: SERCA-2a (Abcam, Cambridge, MA, USA, cat #
ab2861) and GAPDH (EMD Millipore, Billerica, MA, USA, cat
# MAB 374). The secondary antibody was mouse (Santa Cruz
Biotechnology, Dallas, TX, USA, cat # sc 2005). Clarity Western
ECL substrate (BioRad Laboratories, Hercules, CA, USA, catalog
# 170-5061) was used for developing the blots. Densitometric
analysis was carried out using Image Lab software.
Immunoprecipitation
Immunoprecipitation was performed for SERCA-2a using
Protein A dynabeads (Novex, Thermo scientific, Waltham, MA,
USA, cat # 10001D) following the kit’s protocol. Briefly, 4µg
of SERCA-2a antibody (Ab) was added to 50µl of dynabeads.
After incubating at room temperature for 10min, beads were
washed with 1x phosphate buffered saline (1xPBS) with Tween-
20 (0.1%). Diluted heart tissue protein samples (400µg in 500µl
of RIPA) (Ag) were added to the above beads and incubated
for 30min at room temperature. Dynabeads-Ab-Ag complex
was then washed three times in 1xPBS. Bound complex was
eluted using 2x sample buffer (BioRad Laboratories, Hercules,
CA, USA, catalog # 161-0737) followed by 10min heating at
95◦C. Dissociated protein from the beads was collected and
loaded onto the SDS-PAGE gel following the protocol of Western
Blot. Proteins were transferred onto nitrocellulose membrane
and probed by SERCA-2a antibody.
Statistical Analysis
Data were expressed as mean ± SEM. One-way analysis of
variance (ANOVA) and Tuckey’s honest significant difference
(HSD) test was used to determine the differences in means. P <
0.05 was considered significant and represented by “∗”.
RESULTS
Ablation of MMP9 Gene Restores
Cardiomyocyte Contractility in Diabetic
Hearts
We have reported earlier that the rates of contraction (dL/dt)
and relaxation (-dL/dt) of cardiomyocytes are decreased (Mishra
et al., 2010a), and cardiac MMP9 is activated (Mishra et al.,
2010b) in diabetic Akita. To determine whether induction
of MMP9 causes contractile dysfunction in diabetic hearts,
we measured contractility of cardiomyocytes in WT, Akita,
and DKO cardiomyocytes. Our results showed that myocyte
lengthening was decreased in Akita as compared to WT
but it was significantly improved in DKO cardiomyocytes
(Figure 1A). The measurement of ±dL/dt showed that the
rates of contraction and relaxation were decreased in Akita
as compared to WT cardiomyocytes (Figures 1B,C). It was
consistent with the previous report (Mishra et al., 2010a). In
DKO cardiomyocytes ±dL/dt was significantly increased as
compared to Akita cardiomyocytes (Figures 1B,C). Moreover,
we measured the time required for attaining 90% peak height and
90% baseline to assess impaired contractility of cardiomyocytes.
Our results demonstrated that Akita took significantly more
time for 90% peak height and 90% baseline as compared
to WT cardiomyocytes, however, it was restored in DKO
(Figures 1D,E). These results suggest that ablation of MMP9
improves contractility of cardiomyocytes in diabetic hearts.
Abrogation of MMP9 Prolonged Calcium
Transients in Cardiomyocytes of DKO Mice
Calcium transients have important role in regulating contractility
of cardiomyocytes (Boudina and Abel, 2007). Therefore,
we evaluated calcium transients in WT, Akita, and DKO
cardiomyocytes during contraction-relaxation cycle using Fura-
2 AM calcium detection dye. Our results showed that calcium
transients decreased in Akita as compared to WT but improved
in DKO cardiomyocytes (Figure 2A). To determine if decreased
calcium transient was due to increased calcium decay, we
measured the rate of calcium decay in all the three groups.
As expected, the rate of calcium decay was increased in Akita
but restored in DKO cardiomyocytes (Figure 2B). Further,
we measured percentage of calcium ratio for peak height to
baseline, which was decreased in Akita and normalized in DKO
cardiomyocytes (Figure 2C). These results demonstrated that
calcium transient was decreased in Akita and improved in DKO
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FIGURE 1 | Ablation of MMP9 prevents cardiomyocytes contractile dysfunction in diabetic Akita mice. (A) Cardiomyocyte lengthening (µM) and duration of
lengthening was measured in WT, Akita, and DKO hearts. Myocytes were stimulated at 1Hz. (B) The rate of contraction (dL/dt), and (C) rate of relaxation (-dL/dt) was
decreased in Akita but increased in DKO. (D) The time elapsed to attain 90% baseline, and (E) 90% peak height during contractility of cardiomyocytes was increased
in Akita but restored in DKO. Values are mean ± SEM from 15 to 20 cardiomyocytes from each group. N = 4–7. *p < 0.05.
cardiomyocytes suggesting that inhibition of MMP9 improves
calcium transients in cardiomyocytes from diabetic hearts.
Deletion of MMP9 Drives Elevation in
SERCA-2a Expression in Cardiomyocytes
SERCA-2a is one of the important calcium handling proteins
in cardiomyocytes and it is downregulated in diabetic hearts
(Zarain-Herzberg et al., 2014). To determine if reduced level
of SERCA-2a contributed to decreased calcium transients in
Akita and abrogation of MMP9 improved calcium transients by
upregulating SERCA-2a, we measured the mRNA and protein
levels of SERCA-2a in WT, Akita and DKO hearts. QPCR results
showed that SERCA-2a mRNA level was decreased in Akita as
compared to WT hearts. However, it was significantly increased
in DKO as compared to Akita (Figure 3A). Western blotting
and immunoprecipitation results demonstrated that SECRA-2a
protein expression was decreased in Akita and increased in DKO
hearts (Figures 3B,C). These results suggest that inhibiting of
MMP9 improves SERCA-2a expression in diabetic hearts.
Altogether, our results revealed that ablation of MMP9
improves contractility and calcium transients of cardiomyocytes,
plausibly by improving SERCA-2a in diabetic hearts.
DISCUSSION
We observed that in DKO mice, SERCA-2a is upregulated
in the heart, calcium transient is improved, and contractility
is increased in cardiomyocytes as compared to diabetic
Akita (Figures 1–3). In Akita hearts MMP9 is upregulated
(Mishra et al., 2010b) whereas in DKO hearts MMP9 is
abrogated (Mishra et al., 2012), therefore, improvement in
contractility in DKO is plausibly due to ablation of MMP9
gene. We propose that activation of MMP9 downregulates
SERCA-2a, impairs calcium transients, and contractility of
cardiomyocytes, whereas abrogation of MMP9 upregulates
SERCA-2a, improves calcium transients, and contractility of
cardiomyocytes in diabetic hearts (Figure 4). These results
support our hypothesis that MMP9 regulates contractility of
cardiomyocytes in diabetic hearts and ablation of MMP9
prevents cardiomyocytes contractile dysfunction in diabetics.
Considering impaired cardiac contractility as a major cause of
diabetic cardiomyopathy (Malhotra and Sanghi, 1997; Boudina
and Abel, 2007), our results provide a novel role of MMP9 in
diabetic hearts and a novel therapeutic approach for ameliorating
contractile dysfunction of diabetic hearts by suppressing MMP9.
MMP9 is elevated in diabetic (Tayebjee et al., 2004; Mishra
et al., 2010b) and failing (Mann and Spinale, 1998; Thomas
et al., 1998; Buralli et al., 2010; Chu et al., 2013) hearts.
Increased plasma levels of MMP9 is associated with mortality
in humans (Buralli et al., 2010) and with pathological cardiac
remodeling (Halade et al., 2013). We have previously reported
that in cardiomyocytes from C57BL/6J mice, addition of
MMP9 protein decreases contractility whereas pre-treatment
with MMP9 inhibitor TIMP4 on cardiomyocytes blunts the
effect of MMP9 on contractility (Mishra et al., 2010c). However,
the mechanism of MMP9-mediated contractile dysfunction
was unclear. It is reported that plasma MMP9 cleaves
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FIGURE 2 | Abrogation of MMP9 improves cardiomyocytes calcium transients in diabetic Akita mice. (A) Fluorescence ratio of FURA-2 binding to calcium
was recorded from myocytes isolated from WT, Akita, and DKO hearts. Cardiomyocytes were stimulated at 1Hz and calcium ratio was measured during
contraction/relaxation cycle. (B) Rate of calcium decay per second in WT, Akita, and DKO cardiomyocytes showing increased decay in Akita and restoration of decay
in DKO. (C) Calcium released during contraction-relaxation cycle was decreased in Akita but normalized in DKO. Each bar represents mean ± SEM from 15 to 20
cardiomyocytes from each group. N = 4–7. *p < 0.05.
FIGURE 3 | Deletion of MMP9 gene increased the levels of SERCA-2a in diabetic hearts. (A) QPCR showing the mRNA levels of SERCA-2a in WT, Akita, and
DKO hearts. Values are mean ± SEM. N = 5, *P < 0.05. (B) Top, representative Western blot bands for SERCA-2a and GAPDH (a loading control). Bottom, bar graph
showing densitometric analyses of SERCA-2a band intensity. N = 3. Values are mean ± SEM. *P < 0.05. (C) Top, representative immunoprecipitation bands for
SERCA-2a. Bar graphs showing relative expression of SERCA-2a in the three groups. Bottom, bar graph showing the relative values of densitometric band intensity
(arbitrary unit, a. u.) N = 2.
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FIGURE 4 | Schematic showing increased activity of MMP9 in diabetic
hearts is involved in downregulation of SERCA-2a that decreases
calcium transients and impairs contractility of cardiomyocytes.
However, ablation of MMP9 nullifies downregulation of SERCA-2a, improves
calcium transients, and increases contractility of cardiomyocytes in diabetic
hearts.
extracellular domain of β2-adrenergic receptors (Rodrigues
et al., 2010) that induce contractility of cardiomyocytes.
Conversely, pharmacological targeting of β-adrenergic functions
abrogates MMP9 secretion in medulloblastoma cells (Annabi
et al., 2010) suggesting a potential cross-talk between β-
adrenergic receptors and MMP9 (Rietz and Spiers, 2012). The
β-adrenergic receptors induces SERCA-2a at downstream to
increase contractility of cardiomyocytes. Therefore, inhibition of
β-adrenergic receptors signaling suppresses SERCA-2a activity.
Ours results demonstrate that in Akita where MMP9 is activated
(Mishra et al., 2010b) SERCA-2a level is low and in DKO where
MMP9 is abrogated SERCA-2a level is high (Figure 3). It suggests
that MMP9 is involved in regulation of SERCA-2a in diabetic
hearts. Further, it supports the previous reports that MMP9 plays
an important role in contractility of cardiomyocytes.
Although ablation of MMP9 upregulates SERCA-2a in
diabetic hearts, it is unclear whether MMP9 acts through β-
adrenergic receptors at extracellular level, or it directly regulates
SERCA-2a at intracellular level. Previously, it is reported that
mitochondrial MMP9 alters calcium homeostasis and increases
mitochondrial pore transition leading to contractile dysfunction
in hyperhomocysteinemic cardiomyocytes (Moshal et al., 2008a).
It suggests a possible role of MMP9 in calcium signaling-
mediated impairment of SERCA-2a activity in diabetic hearts.
However, more studies are required to confirm it. The role
of MMP9 in regulation of SERCA-2a is also an important
finding because SERCA-2a overexpression improves contractility
of cardiomyocytes obtained from failing human hearts (del
Monte et al., 1999). The improvement in contractility of
cardiomyocytes concomitant with increase in SERCA-2a levels
in DKO heart (Figures 3A–C) supports previous studies showing
that SERCA-2a upregulation mitigates contractile dysfunction of
cardiomyocytes (Giordano et al., 1997; He et al., 1997; del Monte
et al., 1999; Karakikes et al., 2009; Cutler et al., 2012). Our results
also support the cardioprotective effect of inhibition of MMP9
in pathological hearts (Romanic et al., 2002; Lindsey et al., 2006;
Moshal et al., 2008b; Chiao et al., 2012).
We are intrigued to observe that rate of calcium decay
(Figure 2B) and percentage of calcium ratio for peak height
to baseline (Figure 2C) is restored and not blunted in DKO.
This finding supports the crucial role of MMP9 in calcium
homeostasis (Moshal et al., 2008a). Moreover, both rate of
contraction (Figure 1B) and rate of relaxation (Figure 1C) are
blunted in DKO as compared to Akita suggesting that MMP9 in
involved in regulation of both systolic and diastolic dysfunction.
Diabetic hearts at early stage show only diastolic dysfunction
and in later stage progress to systolic dysfunction (Boudina and
Abel, 2007). In 12–14 week male Akita show both diastolic and
systolic dysfunction, which is mitigated by ablation of MMP9
(Figures 1B,C). Therefore, we presume that abrogation ofMMP9
may have potential effects on contractility of diabetic hearts with
diastolic dysfunction.
Altogether, these results provide a novel insight on MMP9-
mediated contractile dysfunction in diabetics and opens a new
window for future studies for cardiac specific role of MMP9 on
contractility in diabetic hearts.
AUTHOR CONTRIBUTIONS
PP wrote the manuscript and contributed in data generation,
NM and SN contributed in data generation, ST contributed
in drafting the manuscript, PM conceptualized the
idea, contributed in generating data, and drafting the
manuscript.
FUNDING
This work was supported, in part, by the National Institutes of
Health grants HL-113281 and HL-116205 to PM, and HL-74185
to ST.
REFERENCES
Annabi, B., Vaillancourt-Jean, E., Weil, A. G., and Beliveau, R. (2010).
Pharmacological targeting of beta-adrenergic receptor functions abrogates NF-
kappaB signaling and MMP-9 secretion in medulloblastoma cells. Onco Targets
Ther. 3, 219–226. doi: 10.2147/OTT.S14503
Boudina, S., and Abel, E. D. (2007). Diabetic cardiomyopathy revisited. Circulation
115, 3213–3223. doi: 10.1161/circulationaha.106.679597
Buralli, S., Dini, F. L., Ballo, P., Conti, U., Fontanive, P., Duranti, E., et al. (2010).
Circulating matrix metalloproteinase-3 and metalloproteinase-9 and tissue
Doppler measures of diastolic dysfunction to risk stratify patients with systolic
heart failure. Am. J. Cardiol. 105, 853–856. doi: 10.1016/j.amjcard.2009.11.038
Chavali, V., Nandi, S. S.,Singh, S. R., and Mishra, P. K. (2014a). Generating double
knockout mice to model genetic intervention for diabetic cardiomyopathy
in humans. Methods Mol. Biol. 1194, 385–400. doi: 10.1007/978-1-4939-12
15-5_22
Frontiers in Physiology | www.frontiersin.org 6 March 2016 | Volume 7 | Article 93
Prathipati et al. MMP9 in Cardiac Contractility
Chavali, V., Tyagi, S. C., and Mishra, P. K. (2014b). Differential expression of
dicer, miRNAs, and inflammatory markers in diabetic Ins2+/- Akita hearts. Cell
Biochem. Biophys. 68, 25–35. doi: 10.1007/s12013-013-9679-4
Chiao, Y. A., Ramirez, T. A., Zamilpa, R., Okoronkwo, S. M., Dai, Q., Zhang, J.,
et al. (2012). Matrix metalloproteinase-9 deletion attenuates myocardial fibrosis
and diastolic dysfunction in ageing mice. Cardiovasc. Res. 96, 444–455. doi:
10.1093/cvr/cvs275
Chu, J. W., Jones, G. T., Tarr, G. P., Phillips, L. V., Wilkins, G. T., van Rij,
A. M., et al. (2013). Plasma active matrix metalloproteinase 9 and indices of
diastolic function in patients with preserved systolic function. Int. J. Cardiol.
167, 1242–1246. doi: 10.1016/j.ijcard.2012.03.147
Cutler, M. J., Wan, X., Plummer, B. N., Liu, H., Deschenes, I., Laurita, K. R.,
et al. (2012).Targeted sarcoplasmic reticulum Ca2+ ATPase 2a gene delivery to
restore electrical stability in the failing heart. Circulation 126, 2095–2104. doi:
10.1161/CIRCULATIONAHA.111.071480
del Monte, F., Harding, S. E., Schmidt, U., Matsui, T., Kang, Z. B., Dec, G. W., et al.
(1999). Restoration of contractile function in isolated cardiomyocytes from
failing human hearts by gene transfer of SERCA2a. Circulation 100, 2308–2311.
doi: 10.1161/01.CIR.100.23.2308
Giordano, F. J., He, H., McDonough, P., Meyer, M., Sayen, M. R., and
Dillmann, W. H. (1997). Adenovirus-mediated gene transfer reconstitutes
depressed sarcoplasmic reticulum Ca2+-ATPase levels and shortens
prolonged cardiac myocyte Ca2+ transients. Circulation 96, 400–403. doi:
10.1161/01.CIR.96.2.400
Halade, G. V., Jin, Y. F., and Lindsey, M. L. (2013). Matrix metalloproteinase
(MMP)-9: a proximal biomarker for cardiac remodeling and a distal
biomarker for inflammation. Pharmacol. Ther. 139, 32–40. doi:
10.1016/j.pharmthera.2013.03.009
He, H., Giordano, F. J., Hilal-Dandan, R., Choi, D. J., Rockman, H. A.,
McDonough, P. M., et al. (1997). Overexpression of the rat sarcoplasmic
reticulum Ca2+ ATPase gene in the heart of transgenic mice accelerates
calcium transients and cardiac relaxation. J. Clin. Invest. 100, 380–389. doi:
10.1172/JCI119544
Karakikes, I., Kim, M., Hadri, L., Sakata, S., Sun, Y., Zhang, W., et al. (2009). Gene
remodeling in type 2 diabetic cardiomyopathy and its phenotypic rescue with
SERCA2a. PLoS ONE 4:e6474. doi: 10.1371/journal.pone.0006474
Lindsey, M. L., Escobar, G. P., Dobrucki, L. W., Goshorn, D. K., Bouges, S.,
Mingoia, J. T., et al. (2006). Matrix metalloproteinase-9 gene deletion facilitates
angiogenesis after myocardial infarction. Am. J. Physiol. Heart Circ. Physiol.
290, H232–H239. doi: 10.1152/ajpheart.00457.2005
Luo, M., and Anderson, M. E. (2013). Mechanisms of altered Ca(2)(+) handling in
heart failure. Circ. Res. 113, 690–708. doi: 10.1161/CIRCRESAHA.113.301651
Malhotra, A., and Sanghi, V. (1997). Regulation of contractile proteins in diabetic
heart. Cardiovasc. Res. 34, 34–40. doi: 10.1016/j.ceca.2014.09.005
Mann, D. L., and Spinale, F. G. (1998). Activation of matrix metalloproteinases in
the failing human heart: breaking the tie that binds. Circulation 98, 1699–1702.
doi: 10.1161/01.CIR.98.17.1699
Mishra, P. K., Givvimani, S., Metreveli, N., and Tyagi, S. C. (2010a). Attenuation
of beta2-adrenergic receptors and homocysteine metabolic enzymes cause
diabetic cardiomyopathy. Biochem. Biophys. Res. Commun. 401, 175–181. doi:
10.1016/j.bbrc.2010.09.006
Mishra, P. K., Metreveli, N., and Tyagi, S. C. (2010c). MMP-9 gene ablation and
TIMP-4 mitigate PAR-1-mediated cardiomyocyte dysfunction: a plausible role
of dicer and miRNA. Cell Biochem. Biophys. 57, 67–76. doi: 10.1007/s12013-
010-9084-1
Mishra, P. K., Tyagi, N., Sen, U., Joshua, I. G., and Tyagi, S. C. (2010b). Synergism
in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol.
Cardiovasc. Diabetol. 9, 49. doi: 10.1186/1475-2840-9-49
Mishra, P. K., Chavali, V.,Metreveli, N., and Tyagi, S. C. (2012). Ablation of MMP9
induces survival and differentiation of cardiac stem cells into cardiomyocytes in
the heart of diabetics: a role of extracellular matrix. Can. J. Physiol. Pharmacol.
90, 353–360. doi: 10.1139/y11-131
Moshal, K. S., Tipparaju, S.M., Vacek, T. P., Kumar,M., Singh,M., Frank, I. E., et al.
(2008a). Mitochondrial matrix metalloproteinase activation decreases myocyte
contractility in hyperhomocysteinemia. Am. J. Physiol. Heart Circ. Physiol. 295,
H890–H897. doi: 10.1152/ajpheart.00099.2008
Moshal, K. S., Rodriguez, W. E., Sen, U., and Tyagi, S. C. (2008b). Targeted
deletion of MMP-9 attenuates myocardial contractile dysfunction in heart
failure. Physiol. Res. 57, 379–384.
Rietz, A., and Spiers, J. (2012). The relationship between the MMP system,
adrenoceptors and phosphoprotein phosphatases. Br. J. Pharmacol. 166,
1225–1243. doi: 10.1111/j.1476-5381.2012.01917.x
Rodrigues, S. F., Tran, E. D., Fortes, Z. B., and Schmid-Schonbein, G. W.
(2010). Matrix metalloproteinases cleave the beta2-adrenergic receptor in
spontaneously hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 299,
H25–H35. doi: 10.1152/ajpheart.00620.2009
Romanic, A. M., Harrison, S. M., Bao, W., Burns-Kurtis, C. L., Pickering, S., Gu,
J., et al. (2002). Myocardial protection from ischemia/reperfusion injury by
targeted deletion of matrix metalloproteinase-9. Cardiovasc. Res. 54, 549–558.
doi: 10.1016/S0008-6363(02)00254-7
Rubler, S., Dlugash, J., Yuceoglu, Y. Z., Kumral, T., Branwood, A. W.,
and Grishman, A. (1972). New type of cardiomyopathy associated with
diabetic glomerulosclerosis. Am. J. Cardiol. 30, 595–602. doi: 10.1016/0002-
9149(72)90595-4
Tayebjee, M. H., Lim, H. S., MacFadyen, R. J., and Lip, G. Y. (2004). Matrix
metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 in type
2 diabetes: effect of 1 year’s cardiovascular risk reduction therapy.Diabetes Care
27, 2049–2051. doi: 10.2337/diacare.27.8.2049
ter Keurs, H. E. (2012). The interaction of Ca2+ with sarcomeric proteins: role in
function and dysfunction of the heart. Am. J. Physiol. Heart Circ. Physiol. 302,
H38–H50. doi: 10.1152/ajpheart.00219.2011
Thomas, C. V., Coker, M. L., Zellner, J. L., Handy, J. R., Crumbley, A. J. III,
and Spinale, F. G. (1998). Increased matrix metalloproteinase activity and
selective upregulation in LV myocardium from patients with end-stage dilated
cardiomyopathy. Circulation 97, 1708–1715. doi: 10.1161/01.CIR.97.17.1708
Zarain-Herzberg, A., Garcia-Rivas, G., and Estrada-Aviles, R. (2014). Regulation
of SERCA pumps expression in diabetes. Cell Calcium 56, 302–310. doi:
10.1016/j.ceca.2014.09.005
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Prathipati, Metreveli, Nandi, Tyagi and Mishra. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Physiology | www.frontiersin.org 7 March 2016 | Volume 7 | Article 93
